MENU
Aim higher

DeFiber

Development of Novel Targeted Drugs for Treatment of Liver Fibrosis

The aim is to develop the first targeted treatment for patients suffering from liver fibrosis (LF). The approach is based on a nanobody-drug-conjugate (NDC), targeted to hepatic stellate cells (HSC), by linking HSC-specific nanobodies to a fibrotic scar diminishing drug, using the proprietary Lx-linker, together called LxL-LF. DeFiber aims to select the best LxL-LF candidate based on in vitro and in vivo studies, and to develop complementary diagnostics, preparing for the (pre-)clinical phases.
Acronym: 
DeFiber
Project ID: 
12 350
Ranking: 
64
Cut-off: 
9
Start date: 
01-10-2018
Project Duration: 
36months
Project costs: 
2 063 160.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Drug delivery and other equipment (including kidney dialysis machines)